Peter Nash

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

Assessment of patients with psoriatic arthritis: a review of currently available measures.

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Tumour necrosis factor inhibitors.

Outcome measures in psoriatic arthritis.

Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.

Therapies for axial disease in psoriatic arthritis. A systematic review.

Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial.

Alefacept plus methotrexate for psoriatic arthritis.

Outcome measures in psoriatic arthritis.

Consensus on a core set of domains for psoriatic arthritis.

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.

Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.

Initiative for quality in psoriasis and psoriatic arthritis.

Drug use and toxicity in psoriatic disease: focus on methotrexate.

Population rates of bone densitometry use in Australia, 2001-2005, by sex and rural versus urban location.

Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.

Assessment and treatment of psoriatic spondylitis.

Inappropriate prescribing for osteoporosis.

Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.

The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy.

Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group.

Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis.

Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health.

Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study.

Registries in systemic sclerosis: a worldwide experience.

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.

Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project).

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.

Cellular blue naevus involving the urinary bladder.

Treatment goals for moderate to severe psoriasis: an Australian consensus.

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Nutrient regulation by continuous feeding removes limitations on cell yield in the large-scale expansion of Mammalian cell spheroids.

The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.

Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.

Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.

Professional boundaries in learning disability care.

An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3.

Updated guidelines for the management of axial disease in psoriatic arthritis.

Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?

A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis.

Treatment Algorithms in Systemic Lupus Erythematosus.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.

Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.

APLAR rheumatoid arthritis treatment recommendations.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.

Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series.

Reply.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Learning disabilities: improved bowel screening.

The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.